The efficacy of spironolactone both in oral and in topical treatment is well known. Nevertheless, oral treatment with spironolactone can cause a lot of systemic antiandrogenic side-effects both in male and in female patients. The aim of this study was to evaluate the systemic absorption of spironolactone and its metabolites (canrenone, 7α-thyomethyl-spironolactone, 6β-hydroxy-7α-thyomethyl-spironolactone) after prolonged topical application in 6 patients affected by acne. The second aim of the study was to evaluate in another group of 14 patients affected by acne, the change in sebum excretion during topical treatment with spironolactone. Results showed that no levels of spironolactone and its metabolites were found in the analyzed plasma samples indicating an antiandrogenic action only at topical level. Moreover, the antiandrogenic activity is characterised by a gradual decrease in sebum excretion especially in patients with high basal levels of seborrhea. This can be explained as a 'normalization' of the androgen receptor activity of sebaceous glands especially in patients with androgenic hyperstimulation.
|Number of pages||5|
|Journal||Annali Italiani di Dermatologia Clinica e Sperimentale|
|Publication status||Published - 1993|
ASJC Scopus subject areas